Core Insights - Senti Biosciences, Inc. announced positive preliminary clinical results for its lead program, SENTI-202, targeting Relapsed/Refractory AML [1] - The company will present these results at the Citizens JMP Life Sciences Conference on May 8, 2025, in New York [1][2] - Senti Bio is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [3] Company Overview - Senti Bio is a clinical-stage biotechnology company dedicated to creating innovative cell and gene therapies for patients with incurable diseases [3] - The company utilizes a synthetic biology platform to engineer Gene Circuits that enhance precision and control in targeting cancer cells while sparing healthy cells [3] - Senti Bio's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [3]

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][4] - The company aims to create therapies that enhance precision and control in targeting cancer cells while sparing healthy cells [4] Lead Program - Senti Bio's lead program, SENTI-202, targets hematologic cancers by focusing on CD33 and/or FLT3 [4] - SENTI-202 is currently enrolling patients in a Phase I clinical trial, indicating progress in clinical development [4] Research and Development - The company has demonstrated preclinical success with its Gene Circuits in T cells, enabling selective targeting of solid tumors [4] - Senti Bio is advancing its capabilities through partnerships and exploring applications of Gene Circuits in other cell and gene therapy modalities beyond oncology [4] Industry Context - The discussion in the Virtual Investor KOL segment highlighted the current treatment landscape for acute myeloid leukemia (AML) and areas of unmet need [3] - The insights from respected leukemia researcher Stephen Strickland, MD, emphasize the significance of Senti Bio's innovative approach in addressing these unmet needs [3]